StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a research note released on Monday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

Shares of OPGN stock opened at $0.53 on Monday. OpGen has a 52-week low of $0.17 and a 52-week high of $3.84. The stock has a market cap of $6.71 million, a PE ratio of -0.08 and a beta of -0.71. The firm’s 50 day moving average price is $0.57 and its two-hundred day moving average price is $0.51.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.